<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02535325</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2015-01408</org_study_id>
    <secondary_id>NCI-2015-01408</secondary_id>
    <secondary_id>CASE 5514</secondary_id>
    <secondary_id>9834</secondary_id>
    <secondary_id>9834</secondary_id>
    <secondary_id>P30CA043703</secondary_id>
    <nct_id>NCT02535325</nct_id>
  </id_info>
  <brief_title>Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer</brief_title>
  <official_title>A Phase I Study of Methoxyamine Combined With Chemo-Radiation for Locally Advanced Non-Squamous Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of methoxyamine when given together&#xD;
      with pemetrexed disodium, cisplatin, and radiation therapy in treating patients with stage&#xD;
      IIIA-IV non-small cell lung cancer. Drugs used in chemotherapy, such as methoxyamine&#xD;
      hydrochloride, pemetrexed disodium, and cisplatin, work in different ways to stop the growth&#xD;
      of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping&#xD;
      them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink&#xD;
      tumors. Giving methoxyamine hydrochloride together with pemetrexed disodium, cisplatin, and&#xD;
      radiation therapy may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose (MTD) of methoxyamine (TRC102) in combination with&#xD;
      pemetrexed disodium (pemetrexed)-cisplatin and thoracic radiotherapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To (descriptively) assess the toxicity profile of methoxyamine (TRC102) in combination&#xD;
      with pemetrexed-cisplatin and thoracic radiotherapy.&#xD;
&#xD;
      II. To (descriptively) assess the short-term progression-free survival at 6 months (PFS6) in&#xD;
      the patients treated on this protocol.&#xD;
&#xD;
      III. To observe and record anti-tumor activity.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of methoxyamine hydrochloride.&#xD;
&#xD;
      CYCLES 1-2: Patients receive pemetrexed disodium intravenously (IV) over 10 minutes and&#xD;
      methoxyamine hydrochloride orally (PO) day 1; and cisplatin IV over 0.5-24 hours on day 3.&#xD;
      Patients also undergo 3-dimensional (3-D) conformal radiation therapy (RT) or&#xD;
      intensity-modulated radiation therapy (IMRT) once daily (QD) 5 days a week (3 days of week 1&#xD;
      and 4 days of week 4) for 30 fractions total.&#xD;
&#xD;
      CYCLES 3-4: Beginning at least 10 days after RT completion, patients receive pemetrexed&#xD;
      disodium IV over 10 minutes and cisplatin IV over 0.5-24 hours on day 1.&#xD;
&#xD;
      Treatment repeats every 21 days for 4 cycles in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 3 weeks and then every 3&#xD;
      months for 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 30, 2015</start_date>
  <primary_completion_date type="Actual">February 27, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of methoxyamine in combination with pemetrexed disodium, cisplatin, and radiation therapy</measure>
    <time_frame>21 days</time_frame>
    <description>Will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. MTD is defined as the highest dose level in which 0/6 or 1/6 patients suffer dose-limiting toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of toxicity of the combination therapy</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will be graded according to NCI CTCAE version 5.0. Toxicity data will be tabulated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>At 6 months</time_frame>
    <description>PFS is analyzed using the Kaplan-Meier method. Factors, such as age, gender, baseline histology and lab correlates including uracil deoxyribonucleic acid (DNA) N-glycosylase (UNG), thymidylate synthase (TS), excision repair cross-complementation group 1 (ERCC1), Ki-67 and Topoisomerase II-alpha (TopoII-alpha) that predict survival will be identified by Cox model or extended Cox model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Disease-free survival is analyzed using the Kaplan-Meier method. Factors, such as age, gender, baseline histology and lab correlates including UNG, TS, ERCC1, Ki-67 and TopoII-alpha that predict survival will be identified by Cox model or extended Cox model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (clinical/tumor response)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The true response rate of the combination therapy for this patient population will be estimated based on the number of responses using a binomial distribution and its confidence intervals will be estimated using Wilson's method. The factors that predict the response will be identified by logistic regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lab correlative expression levels (including UNG, TS, ERCC1, Ki-67 and TopoII-alpha)</measure>
    <time_frame>Baseline to up to 6 months</time_frame>
    <description>The change of lab correlatives measured at baseline and post-treatment will be compared by paired T-test for interval scale measure and McNemar test for nominal measure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma</condition>
  <condition>Stage III Lung Adenocarcinoma AJCC v7</condition>
  <condition>Stage III Lung Large Cell Carcinoma AJCC v7</condition>
  <condition>Stage III Lung Non-Small Cell Cancer AJCC v7</condition>
  <condition>Stage IIIA Lung Adenocarcinoma AJCC v7</condition>
  <condition>Stage IIIA Lung Large Cell Carcinoma AJCC v7</condition>
  <condition>Stage IIIA Lung Non-Small Cell Cancer AJCC v7</condition>
  <condition>Stage IIIB Lung Adenocarcinoma AJCC v7</condition>
  <condition>Stage IIIB Lung Large Cell Carcinoma AJCC v7</condition>
  <condition>Stage IIIB Lung Non-Small Cell Cancer AJCC v7</condition>
  <condition>Stage IV Lung Adenocarcinoma AJCC v7</condition>
  <condition>Stage IV Lung Large Cell Carcinoma AJCC v7</condition>
  <condition>Stage IV Lung Non-Small Cell Cancer AJCC v7</condition>
  <arm_group>
    <arm_group_label>Treatment (pemetrexed, methoxyamine, cisplatin, RT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CYCLES 1-2: Patients receive pemetrexed disodium IV over 10 minutes and methoxyamine hydrochloride PO day 1; and cisplatin IV over 0.5-24 hours on day 3. Patients also undergo 3-D conformal RT or IMRT QD 5 days a week (3 days of week 1 and 4 days of week 4) for 30 fractions total.&#xD;
CYCLES 3-4: Beginning at least 10 days after RT completion, patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 0.5-24 hours on day 1.&#xD;
Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-Dimensional Conformal Radiation Therapy</intervention_name>
    <description>Undergo 3-D conformal RT</description>
    <arm_group_label>Treatment (pemetrexed, methoxyamine, cisplatin, RT)</arm_group_label>
    <other_name>3-dimensional radiation therapy</other_name>
    <other_name>3D Conformal</other_name>
    <other_name>3D CONFORMAL RADIATION THERAPY</other_name>
    <other_name>3D CRT</other_name>
    <other_name>3D-CRT</other_name>
    <other_name>Conformal Therapy</other_name>
    <other_name>Radiation Conformal Therapy</other_name>
    <other_name>Radiation, 3D Conformal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (pemetrexed, methoxyamine, cisplatin, RT)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo IMRT</description>
    <arm_group_label>Treatment (pemetrexed, methoxyamine, cisplatin, RT)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
    <other_name>Radiation, Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methoxyamine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (pemetrexed, methoxyamine, cisplatin, RT)</arm_group_label>
    <other_name>TRC102 Base</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methoxyamine Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (pemetrexed, methoxyamine, cisplatin, RT)</arm_group_label>
    <other_name>TRC 102</other_name>
    <other_name>TRC-102</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (pemetrexed, methoxyamine, cisplatin, RT)</arm_group_label>
    <other_name>MTA</other_name>
    <other_name>Multitargeted Antifolate</other_name>
    <other_name>Pemfexy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed Disodium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (pemetrexed, methoxyamine, cisplatin, RT)</arm_group_label>
    <other_name>Alimta</other_name>
    <other_name>Almita</other_name>
    <other_name>LY231514</other_name>
    <other_name>N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have pathologic diagnosis of adenocarcinoma or large cell carcinoma of&#xD;
             the lung with confirmation by immunohistochemistry (e.g., transcription termination&#xD;
             factor 1 [TTF-1] positivity) (histologic tissue diagnosis is recommended, but cytology&#xD;
             is acceptable); stage IIIA/IIIB or oligometastatic stage IV in which the patient is&#xD;
             still considered an appropriate candidate for aggressive chemoradiotherapy for the&#xD;
             primary tumor; oligometastatic disease is defined as =&lt; 5 metastatic sites (=&lt; 3&#xD;
             lesions per organ); for intracranial metastasis, the patient should have asymptomatic&#xD;
             disease that is stable on steroids or 1 to 3 symptomatic metastatic lesions treated&#xD;
             with stereotactic radiosurgery (SRS)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt; 2&#xD;
&#xD;
          -  Life expectancy of greater than 12 months&#xD;
&#xD;
          -  Ability to swallow and retain orally-administered medication and does not have any&#xD;
             clinically significant gastro-intestinal abnormalities (e.g., malabsorption syndrome&#xD;
             or major resection of the stomach or bowel)&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/mcL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mcL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL&#xD;
&#xD;
          -  Total bilirubin within normal institutional limits&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =&lt;&#xD;
             2.5 x institutional upper limit of normal&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 2.5 x&#xD;
             institutional upper limit of normal&#xD;
&#xD;
          -  Creatinine within normal institutional limits OR&#xD;
&#xD;
          -  Creatinine clearance &gt;= 60 mL/min/1.73 m^2 for patients with creatinine levels above&#xD;
             institutional normal&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL without transfusion within 7 days prior to enrollment&#xD;
&#xD;
          -  The effects of methoxyamine (TRC102) on the developing human fetus are unknown; for&#xD;
             this reason and because methoxyamine as well as other therapeutic agents used in this&#xD;
             trial are known to be teratogenic. women of child-bearing potential and men must agree&#xD;
             to use adequate contraception (hormonal or barrier method of birth control;&#xD;
             abstinence) prior to study entry and for the duration of study participation; should a&#xD;
             woman become pregnant or suspect she is pregnant while she or her partner is&#xD;
             participating in this study, she should inform her treating physician immediately; men&#xD;
             and women treated or enrolled on this protocol must also agree to use adequate&#xD;
             contraception prior to the study, for the duration of study participation, and 4&#xD;
             months after completion of methoxyamine administration&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had prior chemotherapy or any other investigational drug within 30&#xD;
             days of registration or prior radiotherapy to the study treatment volume; prior&#xD;
             surgery is allowed; there must be at least 6 weeks between mitomycin or nitrosoureas&#xD;
             and any new therapy&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents&#xD;
&#xD;
          -  Patients with a history of any active malignancy requiring on-going treatment, except&#xD;
             basal cell carcinoma or squamous cell carcinoma of the skin&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to methoxyamine or to pemetrexed or cisplatin&#xD;
&#xD;
          -  Undetectable haptoglobin or evidence of glucose-6-phophate dehydrogenase (G6PD)&#xD;
             deficiency, pyruvate kinase deficiency, hemoglobinopathy, hereditary spherocytosis,&#xD;
             thalassemia or other disorder associated with hemolysis&#xD;
&#xD;
          -  Patients receiving any medications or substances that are inhibitors or inducers of&#xD;
             nonsteroidal anti-inflammatory drugs (NSAIDS), probenecid, salicylates, sulfonamides&#xD;
             are ineligible; concomitant drugs that are sensitive CYP450 substrates or strong and&#xD;
             moderate CYP450 inducers and inhibitors should be avoided; because the lists of these&#xD;
             agents are constantly changing, it is important to regularly consult a&#xD;
             frequently-updated list; medical reference texts such as the Physicians' Desk&#xD;
             Reference may also provide this information; as part of the enrollment/informed&#xD;
             consent procedures, the patient will be counseled on the risk of interactions with&#xD;
             other agents, and what to do if new medications need to be prescribed or if the&#xD;
             patient is considering a new over-the-counter medicine or herbal product&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Pregnant women are excluded from this study because methoxyamine is an agent with the&#xD;
             potential for teratogenic or abortifacient effects; because there is an unknown but&#xD;
             potential risk for adverse events in nursing infants secondary to treatment of the&#xD;
             mother with methoxyamine, breastfeeding should be discontinued if the mother is&#xD;
             treated with methoxyamine; these potential risks may also apply to other agents used&#xD;
             in this study&#xD;
&#xD;
          -  Patients who are known to be human immunodeficiency positive (HIV)-positive and are on&#xD;
             combination antiretroviral therapy are ineligible because of the potential for&#xD;
             pharmacokinetic interactions with methoxyamine, pemetrexed or cisplatin; in addition,&#xD;
             these patients are at increased risk of lethal infections when treated with&#xD;
             marrow-suppressive therapy; appropriate studies will be undertaken in patients&#xD;
             receiving combination antiretroviral therapy when indicated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tithi Biswas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 27, 2015</study_first_submitted>
  <study_first_submitted_qc>August 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2015</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
    <mesh_term>Carcinoma, Large Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

